Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating) have been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.80.

Several brokerages have commented on IOVA. Wells Fargo & Company restated an "equal weight" rating and issued a $14.00 price objective on shares of Iovance Biotherapeutics in a report on Thursday, August 18th. Truist Financial lowered their price objective on shares of Iovance Biotherapeutics to $18.00 in a report on Tuesday, August 23rd. JMP Securities restated a "buy" rating and issued a $25.00 price objective on shares of Iovance Biotherapeutics in a report on Monday, September 12th. Robert W. Baird decreased their target price on shares of Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a research note on Friday, August 5th. Finally, Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $31.00 to $30.00 in a research note on Friday, August 5th.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Herold Advisors Inc. bought a new stake in shares of Iovance Biotherapeutics during the first quarter valued at approximately $33,000. Spire Wealth Management purchased a new stake in Iovance Biotherapeutics in the first quarter worth approximately $47,000. Lazard Asset Management LLC boosted its holdings in Iovance Biotherapeutics by 38.5% in the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 934 shares during the last quarter. Retirement Group LLC boosted its holdings in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Iovance Biotherapeutics by 1,459.9% in the second quarter. Nisa Investment Advisors LLC now owns 6,614 shares of the biotechnology company's stock worth $73,000 after purchasing an additional 6,190 shares during the last quarter.

Iovance Biotherapeutics Trading Up 0.5 %

Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period last year, the firm posted ($0.53) EPS. Research analysts forecast that Iovance Biotherapeutics will post -2.53 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

(Get Rating)

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.

Featured Articles

• Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
• Magna International is Your Auto and EV One-Stop Shop Stock
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30
• This Is A Memorable Time To Buy Into Micron Technology
• Let Paychex Stock Work Hard For You

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.